Showing 1 - 3 results of 3 for search 'Michael Grundman', query time: 0.01s Refine Results
  1. 1
    A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease

    A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease by Michael Grundman, Roger Morgan, Jason D. Lickliter, Lon S. Schneider, Steven DeKosky, Nicholas J. Izzo, Robert Guttendorf, Michelle Higgin, Julie Pribyl, Kelsie Mozzoni, Hank Safferstein, Susan M. Catalano

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812

    Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT... by Valentina Di Caro, Eunah Cho, Hilary A. North, Jill Caldwell, Kiran Pandey, Duc Duong, Michael Grundman, Willem deHaan, Everard G. Vijverberg, Charlotte E. Teunissen, Anthony O. Caggiano, Nicholas T. Seyfried, Mary E. Hamby

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Low-dose interleukin-2 in patients with mild to moderate Alzheimer’s disease: a randomized clinical trial

    Low-dose interleukin-2 in patients with mild to moderate Alzheimer’s disease: a randomized clinical trial by Alireza Faridar, Nazaret Gamez, Daling Li, Yanling Wang, Reena Boradia, Aaron D. Thome, Weihua Zhao, David R. Beers, Jason R. Thonhoff, Mohammad O. Nakawah, Gustavo C. Román, John J. Volpi, Jon B. Toledo, Michael George, Charles S. Davis, Belen Pascual, Michael Grundman, Joseph C. Masdeu, Stanley H. Appel

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: